Jennifer Teubl's questions to InflaRx (IFRX) leadership • Q3 2019
Question
Jennifer Teubl from Robert W. Baird & Co. asked about the potential timing of a future trial, should regulators give a go-ahead, and requested more granular detail on how many patients in the nonresponder group received a different dosing schedule in the open-label extension compared to the main trial period.
Answer
Executive Niels Riedemann explained that it is too early to speculate on the timing or design of a future study, as it depends on the outcome of regulatory discussions planned in the coming months. He clarified that the nonresponder group (84 patients) and responder group (72 patients) were composed of roughly 14-17 patients from each of the original five treatment arms, noting these small subgroups require cautious interpretation due to high variability.